Tysabri
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2023 | $1.1M | 1,075 | 505 |
| 2022 | $216,098 | 5 | 2 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $722,442 | 260 | 56.0% |
| Unspecified | $471,091 | 9 | 36.5% |
| Travel and Lodging | $57,009 | 169 | 4.4% |
| Food and Beverage | $33,804 | 564 | 2.6% |
| Education | $4,597 | 77 | 0.4% |
| Consulting Fee | $1,226 | 1 | 0.1% |
Payments by Type
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Real-world experience of using Tysabri in 750 MS patients over 15 years in a single US center in the absence of PML - focusing on unique clinical practice in evolution of risk mitigating strategies. | Biogen, Inc. | $92,210 | 1 |
| Evaluating the Effect of Disease Modifying Therapy on Antibody Response to COVID19 Vaccination in People with Multiple Sclerosis | Biogen, Inc. | $84,625 | 0 |
| Biology of a 12-week Planned Interruption of Natalizuamb | Biogen, Inc. | $78,419 | 1 |
| Effect of natalizumab on gray matter and thalamic atrophy: analysis of AFFIRM trial | Biogen, Inc. | $62,524 | 0 |
| EID Columbia and NYU SRA | Biogen, Inc. | $49,880 | 0 |
| A Phase I/II Study of Natalizumab as a Single Agent in Children, Adolescents and Young Adults with Recurrent, Refractory or Progressive Pulmonary Metastatic Osteosarcoma | Biogen, Inc. | $39,127 | 0 |
| Effect of extended interval versus standard interval natalizumab dosing on rates of retinal atrophy in MS | Biogen, Inc. | $33,296 | 0 |
| Brief Proposal for analysis of MS patient who have had greater than 60 infusions of natalizumab | Biogen, Inc. | $21,011 | 0 |
| Comparison of Tysabri, Vumerity, and Ocrevus in MS Patients Stable on Therapy to Characterize Divergent Proteomic, Radiomic, and Clinical Trajectories | Biogen, Inc. | $10,000 | 0 |
Top Doctors Receiving Payments for Tysabri — Page 21
Manufacturing Companies
- Biogen, Inc. $1.3M
Product Information
- Type Biological
- Total Payments $1.3M
- Total Doctors 505
- Transactions 1,080
About Tysabri
Tysabri is a biological associated with $1.3M in payments to 505 healthcare providers, recorded across 1,080 transactions in the CMS Open Payments database. The primary manufacturer is Biogen, Inc..
Payment data is available from 2022 to 2023. In 2023, $1.1M was paid across 1,075 transactions to 505 doctors.
The most common payment nature for Tysabri is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($722,442, 56.0% of total).
Tysabri is associated with 9 research studies, including "Real-world experience of using Tysabri in 750 MS patients over 15 years in a single US center in the absence of PML - focusing on unique clinical practice in evolution of risk mitigating strategies." ($92,210).